Streetbeat News

Price Targets

NXT

Cantor Fitzgerald analyst Derek Soderberg has reiterated an Overweight rating on NEXTracker (NASDAQ:NXT) and maintained a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:48 pm

RKLB

Cantor Fitzgerald analyst Andres Sheppard has initiated coverage on Rocket Lab USA (NASDAQ:RKLB) with an Overweight rating and a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:46 pm

META

Piper Sandler analyst Thomas Champion has maintained an Overweight rating on Meta Platforms (NASDAQ:META) but lowered the price target from $365 to $355.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:37 pm

FBNC

Piper Sandler analyst Stephen Scouten maintains an Overweight rating on First Bancorp (NASDAQ:FBNC) but lowers the price target from $34 to $32.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:34 pm

WSFS

Piper Sandler analyst Frank Schiraldi has maintained a Neutral rating on WSFS Financial (NASDAQ:WSFS) and raised the price target from $37 to $38.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:33 pm

BUSE

Piper Sandler analyst Andrew Liesch maintains an Overweight rating on First Busey (NASDAQ:BUSE) but lowers the price target from $22 to $21.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:30 pm

GPCR

Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and raises the price target from $58 to $93.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:28 pm

EW

Piper Sandler analyst Adam Maeder has maintained a Neutral rating on Edwards Lifesciences (NYSE:EW) and lowered the price target from $83 to $68.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:26 pm

HCSG

Benchmark analyst Bill Sutherland maintains a Buy rating on Healthcare Services Group (NASDAQ:HCSG) but lowers the price target from $18 to $16.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:23 pm

STE

Piper Sandler analyst Jason Bednar maintains a Neutral rating on Steris (NYSE:STE) and lowers the price target from $220 to $215.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 4:20 pm